Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma
Tóm tắt
The clinical use of BRAF inhibitors for treatment of metastatic melanoma is limited by the development of drug resistance. In this study we investigated whether co-targeting the MAPK and the PI3K-AKT pathway can prevent emergence of resistance or provide additional growth inhibitory effects in vitro. Anti-tumor effects of the combination of the BRAF inhibitor (BRAFi) dabrafenib and GSK2141795B (AKTi) in a panel of 23 BRAF mutated melanoma cell lines were evaluated on growth inhibition by an ATP-based luminescent assay, on cell cycle and apoptosis by flow cytometry and on cell signaling by western blot. Moreover, we investigated the possibilities of delaying or reversing resistance or achieving further growth inhibition by combining AKTi with dabrafenib and/or the MEK inhibitor (MEKi) trametinib by using long term cultures. More than 40% of the cell lines, including PTEN-/- and AKT mutants showed sensitivity to AKTi (IC50 < 1.5 μM). The combination of dabrafenib and AKTi synergistically potentiated growth inhibition in the majority of cell lines with IC50 > 5 nM dabrafenib. Combinatorial treatment induced apoptosis only in cell lines sensitive to AKTi. In long term cultures of a PTEN-/- cell line, combinatorial treatment with the MAPK inhibitors, dabrafenib and trametinib, and AKTi markedly delayed the emergence of drug resistance. Moreover, combining AKTi with the MAPK inhibitors from the beginning provided superior growth inhibitory effects compared to addition of AKTi upon development of resistance to MAPK inhibitors in this particular cell line. AKTi combined with BRAFi-based therapy may benefit patients with tumors harboring BRAF mutations and particularly PTEN deletions or AKT mutations.
Tài liệu tham khảo
citation_journal_title=J Transl Med; citation_title=Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032; citation_author=JN Sondergaard, R Nazarian, Q Wang, D Guo, T Hsueh, S Mok, H Sazegar, LE MacConaill, JG Barretina, SM Kehoe, N Attar, E von Euw, JE Zuckerman, B Chmielowski, B Comin-Anduix, RC Koya, PS Mischel, RS Lo, A Ribas; citation_volume=8; citation_publication_date=2010; citation_pages=39; citation_doi=10.1186/1479-5876-8-39; citation_id=CR1
citation_journal_title=Nature; citation_title=Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma; citation_author=G Bollag, P Hirth, J Tsai, J Zhang, PN Ibrahim, H Cho, W Spevak, C Zhang, Y Zhang, G Habets, EA Burton, B Wong, G Tsang, BL West, B Powell, R Shellooe, A Marimuthu, H Nguyen, KY Zhang, DR Artis, J Schlessinger, F Su, B Higgins, R Iyer, K D'Andrea, A Koehler, M Stumm, PS Lin, RJ Lee, J Grippo; citation_volume=467; citation_publication_date=2010; citation_pages=596-599; citation_doi=10.1038/nature09454; citation_id=CR2
citation_journal_title=Lancet; citation_title=Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial; citation_author=A Hauschild, J-J Grob, LV Demidov, T Jouary, R Gutzmer, M Millward, P Rutkowski, CU Blank, WH Miller, E Kaempgen, S Martín-Algarra, B Karaszewska, C Mauch, V Chiarion-Sileni, A-M Martin, S Swann, P Haney, B Mirakhur, ME Guckert, V Goodman, PB Chapman; citation_volume=380; citation_publication_date=2012; citation_pages=358-365; citation_doi=10.1016/S0140-6736(12)60868-X; citation_id=CR3
citation_journal_title=N Engl J Med; citation_title=Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib; citation_author=JA Sosman, KB Kim, L Schuchter, R Gonzalez, AC Pavlick, JS Weber, GA McArthur, TE Hutson, SJ Moschos, KT Flaherty, P Hersey, R Kefford, D Lawrence, I Puzanov, KD Lewis, RK Amaravadi, B Chmielowski, HJ Lawrence, Y Shyr, F Ye, J Li, KB Nolop, RJ Lee, AK Joe, A Ribas; citation_volume=366; citation_publication_date=2012; citation_pages=707-714; citation_doi=10.1056/NEJMoa1112302; citation_id=CR4
citation_journal_title=Biochem Pharmacol; citation_title=Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma; citation_author=IV Fedorenko, KH Paraiso, KS Smalley; citation_volume=82; citation_publication_date=2011; citation_pages=201-209; citation_doi=10.1016/j.bcp.2011.05.015; citation_id=CR5
citation_journal_title=Nature; citation_title=Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation; citation_author=R Nazarian, H Shi, Q Wang, X Kong, RC Koya, H Lee, Z Chen, MK Lee, N Attar, H Sazegar, T Chodon, SF Nelson, G McArthur, JA Sosman, A Ribas, RS Lo; citation_volume=468; citation_publication_date=2010; citation_pages=973-977; citation_doi=10.1038/nature09626; citation_id=CR6
citation_journal_title=Nat Commun; citation_title=Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance; citation_author=H Shi, G Moriceau, X Kong, MK Lee, H Lee, RC Koya, C Ng, T Chodon, RA Scolyer, KB Dahlman, JA Sosman, RF Kefford, GV Long, SF Nelson, A Ribas, RS Lo; citation_volume=3; citation_publication_date=2012; citation_pages=724; citation_doi=10.1038/ncomms1727; citation_id=CR7
citation_journal_title=Nature; citation_title=RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E); citation_author=PI Poulikakos, Y Persaud, M Janakiraman, X Kong, C Ng, G Moriceau, H Shi, M Atefi, B Titz, MT Gabay, M Salton, KB Dahlman, M Tadi, JA Wargo, KT Flaherty, MC Kelley, T Misteli, PB Chapman, JA Sosman, TG Graeber, A Ribas, RS Lo, N Rosen, DB Solit; citation_volume=480; citation_publication_date=2011; citation_pages=387-390; citation_doi=10.1038/nature10662; citation_id=CR8
citation_journal_title=Nature; citation_title=COT drives resistance to RAF inhibition through MAP kinase pathway reactivation; citation_author=CM Johannessen, JS Boehm, SY Kim, SR Thomas, L Wardwell, LA Johnson, CM Emery, N Stransky, AP Cogdill, J Barretina, G Caponigro, H Hieronymus, RR Murray, K Salehi-Ashtiani, DE Hill, M Vidal, JJ Zhao, X Yang, O Alkan, S Kim, JL Harris, CJ Wilson, VE Myer, PM Finan, DE Root, TM Roberts, T Golub, KT Flaherty, R Dummer, BL Weber; citation_volume=468; citation_publication_date=2010; citation_pages=968-972; citation_doi=10.1038/nature09627; citation_id=CR9
citation_journal_title=J Clin Oncol; citation_title=Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling; citation_author=N Wagle, C Emery, MF Berger, MJ Davis, A Sawyer, P Pochanard, SM Kehoe, CM Johannessen, LE Macconaill, WC Hahn, M Meyerson, LA Garraway; citation_volume=29; citation_publication_date=2011; citation_pages=3085-3096; citation_doi=10.1200/JCO.2010.33.2312; citation_id=CR10
citation_journal_title=Proc Natl Acad Sci U S A; citation_title=MEK1 mutations confer resistance to MEK and B-RAF inhibition; citation_author=CM Emery, KG Vijayendran, MC Zipser, AM Sawyer, L Niu, JJ Kim, C Hatton, R Chopra, PA Oberholzer, MB Karpova, LE MacConaill, J Zhang, NS Gray, WR Sellers, R Dummer, LA Garraway; citation_volume=106; citation_publication_date=2009; citation_pages=20411-20416; citation_doi=10.1073/pnas.0905833106; citation_id=CR11
citation_journal_title=N Engl J Med; citation_title=Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations; citation_author=KT Flaherty, JR Infante, A Daud, R Gonzalez, RF Kefford, J Sosman, O Hamid, L Schuchter, J Cebon, N Ibrahim, R Kudchadkar, HA Burris, G Falchook, A Algazi, K Lewis, GV Long, I Puzanov, P Lebowitz, A Singh, S Little, P Sun, A Allred, D Ouellet, KB Kim, K Patel, J Weber; citation_volume=367; citation_publication_date=2012; citation_pages=1694-1703; citation_doi=10.1056/NEJMoa1210093; citation_id=CR12
citation_journal_title=PLoS One; citation_title=Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway; citation_author=M Atefi, E von Euw, N Attar, C Ng, C Chu, D Guo, R Nazarian, B Chmielowski, JA Glaspy, B Comin-Anduix, PS Mischel, RS Lo, A Ribas; citation_volume=6; citation_publication_date=2011; citation_pages=e28973; citation_doi=10.1371/journal.pone.0028973; citation_id=CR13
citation_journal_title=J Invest Dermatol; citation_title=Acquired resistance to BRAF inhibition can confer cross-resistance to combined BRAF/MEK inhibition; citation_author=K Gowrishankar, S Snoyman, GM Pupo, TM Becker, RF Kefford, H Rizos; citation_volume=132; citation_publication_date=2012; citation_pages=1850-1859; citation_doi=10.1038/jid.2012.63; citation_id=CR14
citation_journal_title=Cancer Res; citation_title=Combinatorial treatments that overcome PDGFRbeta-driven resistance of melanoma cells to V600EB-RAF inhibition; citation_author=H Shi, X Kong, A Ribas, RS Lo; citation_volume=71; citation_publication_date=2011; citation_pages=5067-5074; citation_doi=10.1158/0008-5472.CAN-11-0140; citation_id=CR15
citation_journal_title=Cancer Cell; citation_title=Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K; citation_author=J Villanueva, A Vultur, JT Lee, R Somasundaram, M Fukunaga-Kalabis, AK Cipolla, B Wubbenhorst, X Xu, PA Gimotty, D Kee, AE Santiago-Walker, R Letrero, K D'Andrea, A Pushparajan, JE Hayden, KD Brown, S Laquerre, GA McArthur, JA Sosman, KL Nathanson, M Herlyn; citation_volume=18; citation_publication_date=2010; citation_pages=683-695; citation_doi=10.1016/j.ccr.2010.11.023; citation_id=CR16
citation_journal_title=Cancer Discov; citation_title=Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma; citation_author=MR Girotti, M Pedersen, B Sanchez-Laorden, A Viros, S Turajlic, D Niculescu-Duvaz, A Zambon, J Sinclair, A Hayes, M Gore, P Lorigan, C Springer, J Larkin, C Jorgensen, R Marais; citation_volume=3; citation_publication_date=2013; citation_pages=158-167; citation_doi=10.1158/2159-8290.CD-12-0386; citation_id=CR17
citation_journal_title=Front Biosci; citation_title=The RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma; citation_author=F Meier, B Schittek, S Busch, C Garbe, K Smalley, K Satyamoorthy, G Li, M Herlyn; citation_volume=10; citation_publication_date=2005; citation_pages=2986-3001; citation_doi=10.2741/1755; citation_id=CR18
citation_journal_title=J Invest Dermatol; citation_title=Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death, and abrogates invasive growth of melanoma cells; citation_author=KG Lasithiotakis, TW Sinnberg, B Schittek, KT Flaherty, D Kulms, E Maczey, C Garbe, FE Meier; citation_volume=128; citation_publication_date=2008; citation_pages=2013-2023; citation_doi=10.1038/jid.2008.44; citation_id=CR19
citation_journal_title=J Clin Invest; citation_title=Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer; citation_author=A Carracedo, L Ma, J Teruya-Feldstein, F Rojo, L Salmena, A Alimonti, A Egia, AT Sasaki, G Thomas, SC Kozma, A Papa, C Nardella, LC Cantley, J Baselga, PP Pandolfi; citation_volume=118; citation_publication_date=2008; citation_pages=3065-3074; citation_id=CR20
citation_journal_title=Clin Cancer Res; citation_title=The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer; citation_author=T Shimizu, AW Tolcher, KP Papadopoulos, M Beeram, DW Rasco, LS Smith, S Gunn, L Smetzer, TA Mays, B Kaiser, MJ Wick, C Alvarez, A Cavazos, GL Mangold, A Patnaik; citation_volume=18; citation_publication_date=2012; citation_pages=2316-2325; citation_doi=10.1158/1078-0432.CCR-11-2381; citation_id=CR21
citation_journal_title=Cancer Res; citation_title=Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation; citation_author=F Su, WD Bradley, Q Wang, H Yang, L Xu, B Higgins, K Kolinsky, K Packman, MJ Kim, K Trunzer, RJ Lee, K Schostack, J Carter, T Albert, S Germer, J Rosinski, M Martin, ME Simcox, B Lestini, D Heimbrook, G Bollag; citation_volume=72; citation_publication_date=2012; citation_pages=969-978; citation_doi=10.1158/0008-5472.CAN-11-1875; citation_id=CR22
citation_journal_title=J Mol Med (Berl); citation_title=The mitogen-activated protein kinase (MAPK) cascade controls phosphatase and tensin homolog (PTEN) expression through multiple mechanisms; citation_author=L Ciuffreda, C Di Sanza, U Cesta Incani, A Eramo, M Desideri, F Biagioni, D Passeri, I Falcone, G Sette, P Bergamo, A Anichini, K Sabapathy, JA McCubrey, MR Ricciardi, A Tafuri, G Blandino, A Orlandi, R De Maria, F Cognetti, D Del Bufalo, M Milella; citation_volume=90; citation_publication_date=2012; citation_pages=667-679; citation_doi=10.1007/s00109-011-0844-1; citation_id=CR23
citation_journal_title=Biochem Soc Trans; citation_title=Cross-talk between mitogenic Ras/MAPK and survival PI3K/Akt pathways: a fine balance; citation_author=E Aksamitiene, A Kiyatkin, BN Kholodenko; citation_volume=40; citation_publication_date=2012; citation_pages=139-146; citation_doi=10.1042/BST20110609; citation_id=CR24
citation_journal_title=PLoS One; citation_title=BRAFV600E negatively regulates the AKT pathway in melanoma cell lines; citation_author=B Chen, C Tardell, B Higgins, K Packman, JF Boylan, H Niu; citation_volume=7; citation_publication_date=2012; citation_pages=e42598; citation_doi=10.1371/journal.pone.0042598; citation_id=CR25
citation_journal_title=Cancer Res; citation_title=Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells; citation_author=YN Gopal, W Deng, SE Woodman, K Komurov, P Ram, PD Smith, MA Davies; citation_volume=70; citation_publication_date=2010; citation_pages=8736-8747; citation_doi=10.1158/0008-5472.CAN-10-0902; citation_id=CR26
citation_journal_title=Oncogene; citation_title=The PTEN-PI3K pathway: of feedbacks and cross-talks; citation_author=A Carracedo, PP Pandolfi; citation_volume=27; citation_publication_date=2008; citation_pages=5527-5541; citation_doi=10.1038/onc.2008.247; citation_id=CR27
citation_journal_title=Adv Enzyme Regul; citation_title=Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance; citation_author=JA McCubrey, LS Steelman, SL Abrams, JT Lee, F Chang, FE Bertrand, PM Navolanic, DM Terrian, RA Franklin, AB D'Assoro, JL Salisbury, MC Mazzarino, F Stivala, M Libra; citation_volume=46; citation_publication_date=2006; citation_pages=249-279; citation_doi=10.1016/j.advenzreg.2006.01.004; citation_id=CR28
citation_journal_title=J Transl Med; citation_title=Combination therapy with vemurafenib (PLX4032/RG7204) and metformin in melanoma cell lines with distinct driver mutations; citation_author=F Niehr, E von Euw, N Attar, D Guo, D Matsunaga, H Sazegar, C Ng, JA Glaspy, JA Recio, RS Lo, PS Mischel, B Comin-Anduix, A Ribas; citation_volume=9; citation_publication_date=2011; citation_pages=76; citation_doi=10.1186/1479-5876-9-76; citation_id=CR29
citation_journal_title=J Biol Chem; citation_title=Importance of poly(ADP-ribose) polymerase and its cleavage in apoptosis. Lesson from an uncleavable mutant; citation_author=FJ Oliver, G de la Rubia, V Rolli, MC Ruiz-Ruiz, G de Murcia, JM Murcia; citation_volume=273; citation_publication_date=1998; citation_pages=33533-33539; citation_doi=10.1074/jbc.273.50.33533; citation_id=CR30
citation_journal_title=Nature; citation_title=Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE; citation_author=YA Lazebnik, SH Kaufmann, S Desnoyers, GG Poirier, WC Earnshaw; citation_volume=371; citation_publication_date=1994; citation_pages=346-347; citation_doi=10.1038/371346a0; citation_id=CR31
citation_journal_title=N Engl J Med; citation_title=Inhibition of mutated, activated BRAF in metastatic melanoma; citation_author=KT Flaherty, I Puzanov, KB Kim, A Ribas, GA McArthur, JA Sosman, PJ O'Dwyer, RJ Lee, JF Grippo, K Nolop, PB Chapman; citation_volume=363; citation_publication_date=2010; citation_pages=809-819; citation_doi=10.1056/NEJMoa1002011; citation_id=CR32
citation_journal_title=Br J Dermatol; citation_title=Combined targeting of MAPK and AKT signalling pathways is a promising strategy for melanoma treatment; citation_author=F Meier, S Busch, K Lasithiotakis, D Kulms, C Garbe, E Maczey, M Herlyn, B Schittek; citation_volume=156; citation_publication_date=2007; citation_pages=1204-1213; citation_doi=10.1111/j.1365-2133.2007.07821.x; citation_id=CR33
citation_journal_title=Mol Cancer Ther; citation_title=Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases; citation_author=KS Smalley, NK Haass, PA Brafford, M Lioni, KT Flaherty, M Herlyn; citation_volume=5; citation_publication_date=2006; citation_pages=1136-1144; citation_doi=10.1158/1535-7163.MCT-06-0084; citation_id=CR34
citation_journal_title=Sci Transl Med; citation_title=TORC1 Suppression Predicts Responsiveness to RAF and MEK Inhibition in BRAF-Mutant Melanoma; citation_author=RB Corcoran, SM Rothenberg, AN Hata, AC Faber, A Piris, RM Nazarian, RD Brown, JT Godfrey, D Winokur, J Walsh, M Mino-Kenudson, S Maheswaran, J Settleman, JA Wargo, KT Flaherty, DA Haber, JA Engelman; citation_volume=5; citation_publication_date=2013; citation_pages=196ra198; citation_doi=10.1126/scitranslmed.3005753; citation_id=CR35
citation_journal_title=Pigment Cell Melanoma Res; citation_title=Role and therapeutic potential of PI3K-mTOR signaling in de novo resistance to BRAF inhibition; citation_author=W Deng, YN Gopal, A Scott, G Chen, SE Woodman, MA Davies; citation_volume=25; citation_publication_date=2012; citation_pages=248-258; citation_doi=10.1111/j.1755-148X.2011.00950.x; citation_id=CR36
citation_journal_title=J Cell Biol; citation_title=The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins; citation_author=LS Harrington, GM Findlay, A Gray, T Tolkacheva, S Wigfield, H Rebholz, J Barnett, NR Leslie, S Cheng, PR Shepherd, I Gout, CP Downes, RF Lamb; citation_volume=166; citation_publication_date=2004; citation_pages=213-223; citation_doi=10.1083/jcb.200403069; citation_id=CR37
citation_journal_title=Semin Cell Dev Biol; citation_title=PDK1, the master regulator of AGC kinase signal transduction; citation_author=A Mora, D Komander, DM van Aalten, DR Alessi; citation_volume=15; citation_publication_date=2004; citation_pages=161-170; citation_doi=10.1016/j.semcdb.2003.12.022; citation_id=CR38
citation_journal_title=Cancer Discov; citation_title=Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy; citation_author=H Shi, W Hugo, X Kong, A Hong, RC Koya, G Moriceau, T Chodon, R Guo, DB Johnson, KB Dahlman, MC Kelley, RF Kefford, B Chmielowski, JA Glaspy, JA Sosman, N van Baren, GV Long, A Ribas, RS Lo; citation_volume=4; citation_publication_date=2014; citation_pages=80-93; citation_doi=10.1158/2159-8290.CD-13-0642; citation_id=CR39
citation_journal_title=Cancer Discov; citation_title=The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma; citation_author=EM Van Allen, N Wagle, A Sucker, DJ Treacy, CM Johannessen, EM Goetz, CS Place, A Taylor-Weiner, S Whittaker, GV Kryukov, E Hodis, M Rosenberg, A McKenna, K Cibulskis, D Farlow, L Zimmer, U Hillen, R Gutzmer, SM Goldinger, S Ugurel, HJ Gogas, F Egberts, C Berking, U Trefzer, C Loquai, B Weide, JC Hassel, SB Gabriel, SL Carter, G Getz; citation_volume=4; citation_publication_date=2014; citation_pages=94-109; citation_doi=10.1158/2159-8290.CD-13-0617; citation_id=CR40
citation_journal_title=Cancer Discov; citation_title=MAP Kinase Pathway Alterations in BRAF-Mutant Melanoma Patients with Acquired Resistance to Combined RAF/MEK Inhibition; citation_author=N Wagle, EM Van Allen, DJ Treacy, DT Frederick, ZA Cooper, A Taylor-Weiner, M Rosenberg, EM Goetz, RJ Sullivan, DN Farlow, DC Friedrich, K Anderka, D Perrin, CM Johannessen, A McKenna, K Cibulskis, G Kryukov, E Hodis, DP Lawrence, S Fisher, G Getz, SB Gabriel, SL Carter, KT Flaherty, JA Wargo, LA Garraway; citation_volume=4; citation_publication_date=2014; citation_pages=61-68; citation_doi=10.1158/2159-8290.CD-13-0631; citation_id=CR41